Cytrellis Biosystems Expands into South Korean Aesthetic Market
News related to:Cytrellis Biosystems Inc · 2 min read
WOBURN, Mass., Sept. 29, 2026 /CourierPR/ -- Cytrellis Biosystems Inc., a company specializing in skin health and restoration, has entered into a strategic partnership with KoreAx Co. Ltd. to commercialize its ellacor® Micro-Coring® technology in South Korea. This move marks a significant step for the company, as it aims to tap into one of the world's most advanced and high-volume aesthetic markets.
Approved by the Korean Ministry of Food and Drug Safety in 2025, ellacor® is the first and only FDA-cleared, minimally invasive, in-office procedure that removes sagging skin without surgery or thermal energy. The technology offers a unique solution for addressing skin laxity, providing a non-invasive alternative for patients seeking to address moderate to severe wrinkles.
South Korea is one of the fastest-growing and most influential markets for aesthetic treatments, with a strong demand for minimally invasive procedures. The medical aesthetics market in Korea was estimated at $572 million in 2023 and is projected to reach $1.1 billion by 2029, driven by the growing preference for non-surgical treatments that offer noticeable results with minimal downtime.
The launch in South Korea will be executed in partnership with KoreAx, which brings deep expertise in the aesthetics sector and an extensive network of key opinion leaders and clinics. This collaboration will ensure effective training, education, and market penetration aligned with local needs.
The Korean commercial launch marks the second major international market expansion for the company in 2026, following its earlier launch in Australia. Together, these markets expand the company's global footprint and support continued procedure volume and revenue growth.
ellacor® with Micro-Coring® technology is indicated for use by qualified medical professionals in adults aged 22 years or older, with Fitzpatrick skin types I-IV. The technology is designed to remove excess skin to address moderate and severe wrinkles, offering a non-surgical alternative for skin restoration.
This strategic move by Cytrellis Biosystems Inc. underscores its commitment to advancing the frontier of skin restoration and meeting the evolving needs of patients seeking effective, safe, and innovative solutions.